Evidence map›Paper›PMID 35797133›Full record

ArticleJCI insight2022

Altered branched-chain α-keto acid metabolism is a feature of NAFLD in individuals with severe obesity.

Thomas Grenier-Larouche, Lydia Coulter Kwee, Yann Deleye, Paola Leon-Mimila, Jacquelyn M Walejko, Robert W McGarrah, Simon Marceau, Sylvain Trahan, Christine Racine, André C Carpentier and 8 more

Open access · goldAbstract read
In one paragraph

Article in JCI insight, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
6.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 42 citations in OpenAlex.

  1. Trial
  2. The effects of low-fat dairy products fortified with 1500 IU vitamin DJournal of health, population, and nutrition · 2023
    Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. MASH: the nexus of metabolism, inflammation, and fibrosis.The Journal of clinical investigation · 2025
    Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Branched-chain amino acid metabolism: Pathophysiological mechanism and therapeutic intervention in metabolic diseases.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2025
    Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 3 countries.

Thomas Grenier-LaroucheSarah W. Stedman Nutrition and Metabolism Center and Duke Molecular Physiology Institute, Duke University Medical Center, Divisions of Endocrinology and Cardiology, Department of Medicine, and Department of Pharmacology and Cancer Biology, Durham, North Carolina, USA.
Lydia Coulter KweeSarah W. Stedman Nutrition and Metabolism Center and Duke Molecular Physiology Institute, Duke University Medical Center, Divisions of Endocrinology and Cardiology, Department of Medicine, and Department of Pharmacology and Cancer Biology, Durham, North Carolina, USA.
Yann DeleyeSarah W. Stedman Nutrition and Metabolism Center and Duke Molecular Physiology Institute, Duke University Medical Center, Divisions of Endocrinology and Cardiology, Department of Medicine, and Department of Pharmacology and Cancer Biology, Durham, North Carolina, USA.
Paola Leon-MimilaDepartment of Medicine/Division of Cardiology, UCLA, California, USA.
Jacquelyn M WalejkoSarah W. Stedman Nutrition and Metabolism Center and Duke Molecular Physiology Institute, Duke University Medical Center, Divisions of Endocrinology and Cardiology, Department of Medicine, and Department of Pharmacology and Cancer Biology, Durham, North Carolina, USA.
Robert W McGarrahSarah W. Stedman Nutrition and Metabolism Center and Duke Molecular Physiology Institute, Duke University Medical Center, Divisions of Endocrinology and Cardiology, Department of Medicine, and Department of Pharmacology and Cancer Biology, Durham, North Carolina, USA.
Simon MarceauInstitut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Quebec City, Quebec, Canada.
Sylvain TrahanInstitut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Quebec City, Quebec, Canada.
Christine RacineInstitut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Quebec City, Quebec, Canada.
André C CarpentierFaculty of Medicine and Health Sciences, Centre de recherche du Centre hospitalier universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, Quebec, Canada.
Aldons J LusisDepartment of Medicine/Division of Cardiology, UCLA, California, USA.
Olga IlkayevaSarah W. Stedman Nutrition and Metabolism Center and Duke Molecular Physiology Institute, Duke University Medical Center, Divisions of Endocrinology and Cardiology, Department of Medicine, and Department of Pharmacology and Cancer Biology, Durham, North Carolina, USA.
Marie-Claude VohlCentre de Nutrition, Santé et Société and Institute of Nutrition and Functional Foods, Université Laval, Quebec City, Quebec, Canada.
Adriana Huertas-VazquezDepartment of Medicine/Division of Cardiology, UCLA, California, USA.
André TchernofInstitut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Quebec City, Quebec, Canada.
Svati H ShahSarah W. Stedman Nutrition and Metabolism Center and Duke Molecular Physiology Institute, Duke University Medical Center, Divisions of Endocrinology and Cardiology, Department of Medicine, and Department of Pharmacology and Cancer Biology, Durham, North Carolina, USA.
Christopher B NewgardSarah W. Stedman Nutrition and Metabolism Center and Duke Molecular Physiology Institute, Duke University Medical Center, Divisions of Endocrinology and Cardiology, Department of Medicine, and Department of Pharmacology and Cancer Biology, Durham, North Carolina, USA.
Phillip J WhiteSarah W. Stedman Nutrition and Metabolism Center and Duke Molecular Physiology Institute, Duke University Medical Center, Divisions of Endocrinology and Cardiology, Department of Medicine, and Department of Pharmacology and Cancer Biology, Durham, North Carolina, USA.
Duke University · USInstitut universitaire de cardiologie et de pneumologie de Québec · CAUCLA Health · USCentre Hospitalier Universitaire de Sherbrooke · CAUniversité Laval · CA

Funding

TARGETED RESPONSIVE MR AND PET AGENTS FOR B-CELL IMAGINGP01DK058398 · NIDDK · UNIVERSITY OF TEXAS SW MED CTR/DALLAS · PI NEWGARD, CHRISTOPHER B · 2000 to 2016
$26.1M
Pilot & Feasibility ProgramP30DK124723 · NIDDK · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI P Darrell Neufer · 2020 to 2026
$11.0M
Mechanisms connecting dysregulated BCAA, glucose & lipid metabolism in the pathogenesis of metabolic diseaseR01DK121710 · NIDDK · DUKE UNIVERSITY · PI HERMAN, MARK A, NEWGARD, CHRISTOPHER B · 2019 to 2022
$2.7M
A Personalized Metabolomic Approach to Human Obesity and Weight LossR01HL127009 · NHLBI · DUKE UNIVERSITY · PI SHAH, SVATI H. · 2016 to 2019
$2.1M
NHLBI NIH HHS R01 HL127009NIDDK NIH HHS P01 DK058398NIDDK NIH HHS P30 DK124723NIDDK NIH HHS R01 DK121710
6 · The paper itself

Abstract

Hepatic de novo lipogenesis is influenced by the branched-chain α-keto acid dehydrogenase (BCKDH) kinase (BCKDK). Here, we aimed to determine whether circulating levels of the immediate substrates of BCKDH, the branched-chain α-keto acids (BCKAs), and hepatic BCKDK expression are associated with the presence and severity of nonalcoholic fatty liver disease (NAFLD). Eighty metabolites (3 BCKAs, 14 amino acids, 43 acylcarnitines, 20 ceramides) were quantified in plasma from 288 patients with bariatric surgery with severe obesity and scored liver biopsy samples. Metabolite principal component analysis factors, BCKAs, branched-chain amino acids (BCAAs), and the BCKA/BCAA ratio were tested for associations with steatosis grade and presence of nonalcoholic steatohepatitis (NASH). Of all analytes tested, only the Val-derived BCKA, α-keto-isovalerate, and the BCKA/BCAA ratio were associated with both steatosis grade and NASH. Gene expression analysis in liver samples from 2 independent bariatric surgery cohorts showed that hepatic BCKDK mRNA expression correlates with steatosis, ballooning, and levels of the lipogenic transcription factor SREBP1. Experiments in AML12 hepatocytes showed that SREBP1 inhibition lowered BCKDK mRNA expression. These findings demonstrate that higher plasma levels of BCKA and hepatic expression of BCKDK are features of human NAFLD/NASH and identify SREBP1 as a transcriptional regulator of BCKDK.

Indexed as

Non-alcoholic Fatty Liver DiseaseObesity, MorbidAmino Acids, Branched-ChainHumansKeto AcidsRNA, MessengerAmino Acids, Branched-ChainKeto AcidsRNA, MessengerAmino acid metabolismHepatologyMetabolismObesity

Identifiers

PMID35797133
PMCPMC9462486
OpenAlexW4284697415

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.